Press Releases

10.14.21
OpGen Announces $15 Million Registered Direct Offering
10.04.21
OpGen Provides Business Update and Announces Preliminary Unaudited Revenue and Cash Position for Third Quarter 2021
10.04.21
OpGen Receives FDA Clearance for Acuitas® AMR Gene Panel
09.30.21
OpGen Initiates Clinical Trial for Unyvero Urinary Tract Infection Panel
09.15.21
OpGen Announces Data from Prospective Randomized Controlled Multicenter Clinical Study Using the Unyvero HPN Panel for Hospitalized Patients with Suspicion of Pneumonia
08.12.21
OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update
08.04.21
OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting
08.04.21
OpGen to Provide Business Update and Financial Results for the Second Quarter 2021 on August 12th at 4:30 p.m. Eastern Time
08.03.21
OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program
07.07.21
OpGen Announces Partial Adjournment of Annual Meeting